Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2016 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce fourth quarter and fiscal year 2015 ended December 31, 2015 financial results and host a conference call and webcast on Thursday, March 3.
Conference Call & Webcast
Thursday, March 3, 2016 @ 8am Eastern Time
| Toll Free: | 888-329-8862 | ||||
| International: | 719-325-2361 | ||||
| Conference ID: | 1046957 | ||||
| Webcast: | http://public.viavid.com/index.php?id=118418 | ||||
| Replays, through March 17th | |||||
| Toll-Free: | 877-870-5176 | ||||
| International: | 858-384-5517 | ||||
| Conference ID: | 1046957 | ||||
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.
Contact: Ilan Hadar, CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 [email protected] US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 [email protected]
